GBE1
1,4-alpha-glucan-branching enzyme
Also known as: GLGB_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q04446
- Gene
- GBE1
- Ensembl
- ENSG00000114480
- Chromosome
- 3
- Canonical length
- 702 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
The protein encoded by this gene is a glycogen branching enzyme that catalyzes the transfer of alpha-1,4-linked glucosyl units from the outer end of a glycogen chain to an alpha-1,6 position on the same or a neighboring glycogen chain. Branching of the chains is essential to increase the solubility of the glycogen molecule and, consequently, in reducing the osmotic pressure within cells. Highest level of this enzyme are found in liver and muscle. Mutations in this gene are associated with glycogen storage disease IV (also known as Andersen's disease). [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
702 residues, UniProt reviewed canonical sequence.
>Q04446|GBE1
1 MAAPMTPAAR PEDYEAALNA ALADVPELAR LLEIDPYLKP YAVDFQRRYK QFSQILKNIG
61 ENEGGIDKFS RGYESFGVHR CADGGLYCKE WAPGAEGVFL TGDFNGWNPF SYPYKKLDYG
121 KWELYIPPKQ NKSVLVPHGS KLKVVITSKS GEILYRISPW AKYVVREGDN VNYDWIHWDP
181 EHSYEFKHSR PKKPRSLRIY ESHVGISSHE GKVASYKHFT CNVLPRIKGL GYNCIQLMAI
241 MEHAYYASFG YQITSFFAAS SRYGTPEELQ ELVDTAHSMG IIVLLDVVHS HASKNSADGL
301 NMFDGTDSCY FHSGPRGTHD LWDSRLFAYS SWEILRFLLS NIRWWLEEYR FDGFRFDGVT
361 SMLYHHHGVG QGFSGDYSEY FGLQVDEDAL TYLMLANHLV HTLCPDSITI AEDVSGMPAL
421 CSPISQGGGG FDYRLAMAIP DKWIQLLKEF KDEDWNMGDI VYTLTNRRYL EKCIAYAESH
481 DQALVGDKSL AFWLMDAEMY TNMSVLTPFT PVIDRGIQLH KMIRLITHGL GGEGYLNFMG
541 NEFGHPEWLD FPRKGNNESY HYARRQFHLT DDDLLRYKFL NNFDRDMNRL EERYGWLAAP
601 QAYVSEKHEG NKIIAFERAG LLFIFNFHPS KSYTDYRVGT ALPGKFKIVL DSDAAEYGGH
661 QRLDHSTDFF SEAFEHNGRP YSLLVYIPSR VALILQNVDL PNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GBE1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.21
- Highest tissue expression
- 142 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 142 nTPM
- liver: 102 nTPM
- adipose tissue: 69 nTPM
- tongue: 53 nTPM
- heart muscle: 52 nTPM
- adrenal gland: 51 nTPM
Single-cell type
- myonuclei: 1,503 nCPM
- adipocytes: 1,160 nCPM
- thymic myoid cells: 1,080 nCPM
- neutrophil progenitors: 887 nCPM
- neutrophils: 638 nCPM
- cardiomyocytes: 621 nCPM
Immune cell
- eosinophil: 16 nTPM
- myeloid DC: 14 nTPM
- NK-cell: 14 nTPM
- naive B-cell: 13 nTPM
- non-classical monocyte: 12 nTPM
- classical monocyte: 12 nTPM
Brain region
- midbrain: 39 nTPM
- choroid plexus: 29 nTPM
- medulla oblongata: 21 nTPM
- pons: 21 nTPM
- cerebral cortex: 16 nTPM
- hypothalamus: 16 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GBE1.
Disease | AllUniProt
Conditions GBE1 is implicated in, by any mechanism.
- Glycogen storage disease 4 (GSD4) MIM:232500
- Polyglucosan body neuropathy, adult form (APBN) MIM:263570
Disease | GeneticClinVar
206 pathogenic / likely-pathogenic of 1,122 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Glycogen storage disease, type IV
- Glycogen storage disease IV, classic hepatic
- Adult polyglucosan body disease
- GBE1-related disorder
- Glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.97
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.09
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- generation of precursor metabolites and energy
- glycogen biosynthetic process
- glycogen metabolic process
- negative regulation of neuron apoptotic process
Molecular functions
- carbohydrate binding
- cation binding
- hydrolase activity, hydrolyzing O-glycosyl compounds
- 1,4-alpha-glucan branching enzyme activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Glycosyl hydrolase family 13, catalytic domain
- Alpha-amylase/branching enzyme, C-terminal all beta
- Glycosyl hydrolase, all-beta
- Immunoglobulin-like fold
- Immunoglobulin E-set
- Glycoside hydrolase superfamily
- Alpha amylase, catalytic domain
- Alpha amylase, C-terminal all-beta domain
- Glycoside hydrolase, family 13, N-terminal
- 1,4-alpha-glucan-branching enzyme
- Carbohydrate-binding module 48 (Isoamylase N-terminal domain)
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GBE1 as an antibody target. Whether an autoantibody or antibody against GBE1 could matter depends on whether native GBE1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GBE1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label GBE1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...